Cullinan Pearl Announces Presentation of Preliminary Safety and Efficacy of CLN-081 in EGFR Exon 20 NSCLC Patients at ESMO Virtual Congress 2020 Cullinan Pearl Announces Presentation of Preliminary Safety and Efficacy of CLN-081 in EGFR Exon 20 NSCLC Patients at ESMO Virtual Congress 2020 Matt Burke2020-09-17T08:47:26-05:00September 17, 2020| Read More
Fueled with a fresh cash injection, Cullinan expands its pipeline with a bid to develop a new combination drug for the checkpoint class Matt Burke2020-09-17T10:51:19-05:00June 12, 2020| Read More
Cullinan Oncology Announces First Patients Dosed with Drug Candidates from Cullinan Apollo and Cullinan Pearl Cullinan Oncology Announces First Patients Dosed with Drug Candidates from Cullinan Apollo and Cullinan Pearl Matt Burke2019-12-18T21:30:52-05:00December 18, 2019| Read More
Cullinan Oncology CSO and MPM Capital Executive Partner Patrick Baeuerle Wins 2019 Xconomy “X of the Year” Award Matt Burke2020-07-23T19:30:24-05:00September 26, 2019| Read More
